CEL-SCI Corporation (CVM) Cash Flow Statement

The persistent gap between net income and operating cash flow suggests that non-cash expenses, such as stock-based compensation and depreciation, are significant components of the company's reported losses. Investors should monitor this relationship closely, as the inability to generate positive operating cash flow necessitates ongoing dilution to sustain the current clinical development trajectory.

The absence of a positive free cash flow trend indicates that the company is entirely dependent on capital markets to maintain its operations. This trajectory implies that any delay in regulatory milestones or clinical data validation will likely exacerbate the existing cash burn, further increasing the probability of dilutive equity offerings.

The low capital intensity reflects a strategic focus on preserving cash for clinical trial management rather than asset acquisition. However, this lack of investment may also indicate that the company is not currently scaling its manufacturing capacity, which could pose a bottleneck if regulatory approval for Multikine is eventually granted.